clinical trial · NCT07502001
Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.·phase1·not yet recruiting·n = 42
OverweightObesityAcetaminophenMetforminWarfarinAtorvastatinDigoxinHDM1005 injection
brief summary
The purpose of this study is to characterize the Influence of HDM1005 on gastric emptying and drug-drug interaction of HDM1005 and metformin, atorvastatin, warfarin, and digoxin in overweight/obese adult subjects.
started
Apr 8, 2026
primary completion
Dec 1, 2026
completion
Jun 2, 2027
last updated
Mar 30, 2026
official title
A Phase I, Single-center, Open-Label, Single-Arm, Fixed-Sequence Study to Evaluate the Influence of HDM1005 on Gastric Emptying and Drug-Drug Interaction of HDM1005 and Metformin, Atorvastatin, Warfarin, and Digoxin in Overweight/Obese Adult Chinese Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol